TOLERA trial in RA RTX/ABA sequence versus RTX alone 10pts each group Primary outcome was ambitious: ACPA seroconversion No difference between ttmts (and also no seroconversion) No diff in disease activity No diff in ACPA change wt wk52 @RheumNow OP0069 #EULAR2024 https://t.co/0EM7XRzfNo

• https://twitter.com/AurelieRheumo/status/1800946507190870218/photo/1

AMPLIFIED RCT, 300+ pts ABA NOT (!) superior to ADA in dual seropositive SE+ MTX IR RA pts ACR50 rate high in both gps ABA 59% vs ADA 64% No new safety signal Defeating the encouraging data from smaller trials Abstr#OP0007 #EULAR2024 @RheumNow https://t.co/PvRUnpthHl

• https://twitter.com/AurelieRheumo/status/1800938588101599607/photo/1

Reminder of relevance of #Rheumatoid factor ⬆️RF also predicts cardiovascular events ⚠️ ⬆️disease activity ❗️Worse outcomes #EULAR2024 #RF #RA https://t.co/kXwh682ONp

• https://twitter.com/gurdeep_dulay/status/1800935105009000749/photo/1

What is new in RA at #EULAR2024? Below 👇🏻 my article summarising some of the exciting new MoA, therapeutic strategies and drugs that might (or not) shape RA future! https://t.co/ttYdElWlBY @RheumNow

• Encurtador de Link

🚨New(ish) MoA in RA Abiprubart anti-CD40 mAb Blocks T cell activation Reduction DAS28-CRP Wk 12 -2.2 vs. -1.6 PBO Small sample n=25 per gpe Safety profile acceptable To be continued... Abstr#OP0036 #EULAR2024 @RheumNow https://t.co/su4L7A7nGJ

• https://twitter.com/AurelieRheumo/status/1800933979584917902/photo/1

Substudy of SELECT-COMPARE trial Week 60 immunogenicity RZV RA treated UPA 15 mg + MTX ✔️ HUmorale response 71% ✔️ Cellular response 65% ✔️ No serious AEs ✔️ One event of HZ occurred during follow up Abstr#OP0020 #EULAR2024 @RheumNow https://t.co/8OMwGuIZFx

• https://twitter.com/AurelieRheumo/status/1800934293604098449/photo/1

Novel B cell depleters! Bispecific T cell engagers (BiTEs) being studied for #SLE & #RA as a way to get CAR-T cell like responses but more accessible w/less risk for CK release syndrome. #EULAR24 T cell-engaging therapies — BiTEs and beyond | Nature Reviews Clinical Oncology

Nordic country analysis of mortality in RA (n 1145), RA-ILD (239), population ILD (378) & nl controls (1890) shows most mortality in pop ILD (HR 8.3), but less in RA-ILD (HR 3.6). Why is death less in latter; could it be RA therapies? Abstr #POS0022 # EULAR2025 https://t.co/wFZq49rIiW

More data from Jak-pot, the real-world multinational RA study, this time looking at infection in 14 national registries JAKi (vs TNFi) had no signal for general/serious infection (excluding HZ) Somewhat reassuring post-ORAL Surveillance infection data #EULAR2024 OP0092 @RheumNow https://t.co/ocAbc4NiV2

• https://twitter.com/drdavidliew/status/1800922236372791605/photo/1